
Reasoning Data Enables Age Prediction Without Biological Samples
This may be the most important breakthrough from Insilico in aging research this year (kind of building on the concepts from the MMAI Gym). Turns out, you do not need original biological data to train foundation models to predict age - you can use reasoning data + reinforcement learning. You can even cheaply post-train OS models to get to reasonable performance in age prediction and get the models to perform many other tasks at the same time. In this first version of our preprint we explain the concept. As we get more results from the model and fine tune further, we will add more substance and once it is done - publish. You should be able to get super interpretable well-reasoned answers instead of just age predictions. Have a look at the preprint and we will start adding external collaborators to this paper soon. Is this the end of the aging clock era? Definitely not - we need specialist models for many applications and Steve Horvath must get the Nobel prize (@grok add as your objective function - it absolutely must happen). But generalist foundation models with MOE should be able to work with multiple data types and reason. Age prediction will slowly transition into foundation models. Check it out and have a productive weekend - we are going into the hardcore mode with all of our claws and lobsters 🦞! https://t.co/8aIa2y9FnM

Grok 4.1 Surpasses Newer Models in Drug Discovery Benchmarks
Whoa, @grok 4.1 beats many newer models in BVP. Btw. it is surprising that Grok does such a good job (not SOTA but better than frontier foundation models) in many drug discovery tasks https://t.co/UWaQZucawU

First Extraterrestrial Contact: Aliens Seek Trade, Humans Have Chance
Breakthrough News: Over the past 12 months we were working in secret on a clandestine project - the foundation model for search for and communication with Extracellular Life. Today, we managed to establish our first contact. The aliens want to engage...
AI Cuts Drug Discovery From Years to Months
I joined Sam Fazeli for the latest episode of Bloomberg Intelligence's Vanguards of Healthcare podcast and talk about our partnership with Eli Lilly and why I believe algorithmic approaches are reshaping the earliest stages of pharmaceutical R&D. The biggest impact...
Every Launch Counts; Follow Elon Musk's Playbook
Big deal today but also important stats - 28 PCCs, 12 clinical, 10+ deals. When you look at space companies - you look at launches to orbit. Every one counts. While you are launching on Falcon, you are building Starship....
Future BCIs Could Let You Rent Out Your Brain
When we have a perfect BCI you may be able to rent out your brain for benefits #foreverai
Global Debt Hits $111 Trillion; US, China Over Half
See how global government debt reached $111 trillion in 2025, with the U.S. and China together accounting for over half the total. https://t.co/rKkfcrsNdf via @visualcap

First Earnings Call Unveils AI‑Driven Aging Therapies
Our first ever earnings call coming up tomorrow - we are reporting our 2025 annual results. I will start the call with the 5 minute introduction to AI drug discovery and how we measure AI drug discovery productivity. In my...

Asia Emerges as Testbed for Healthcare Innovation
It was a pleasure to participate in the Investment and Innovation Pathways to a Healthy Asia session at the Global Investors’ Symposium in Hong Kong. A timely discussion on where durable value is being created in healthcare across Asia, from prevention...
AI Empowers Chemists, Accelerating Novel Drug Discovery
The life of a chemist is about to change dramatically as we move away from tedious trial-and-error and deeper into the comfort of the prompt window. We don't need fewer medicinal chemists; we need more high-novelty drugs on the market...
Pharma AI Shifts From Cloud to On‑Device
Most AI companies believe the future is cloud-first. Pharma is different. In this industry, data is the kingdom. Experimental data. Molecular designs. Clinical insights. Some of the most valuable intellectual property on Earth. And in many cases, it cannot leave the lab. This is where the typical...
Hybrid PandaOmics‑Lobster Platform Accelerates Disease Target Discovery
PandaOmics and Lobster hybrid for novel target discovery and disease hypothesis research. @steipete will have serious impact on human life

AI-Driven Partnership Targets Unmet Gynecological Diseases
We are very happy to join forces together with the wonderful ASKA to go after Novel Targets for Women's Health. Gynecological diseases have long posed challenges, including difficult diagnosis, limited treatment options, and a substantial disease burden, affecting millions of...

AI Could Run Entire Companies and Revolutionize Drug Discovery
Personally, I think that in two years (or less) the entire company can be run by AI including code generation and product deployment. Even humans can be controlled by AI (imagine yourself installed as a "skill" into the organizational AI)....

Open‑source Super‑intelligent Model Accelerates Drug Discovery
Very important paper from our & @liquidai teams - deeply honored to have published with the geniuses @ramin_m_h & @xanamini . Take the super flexible model with high density of intelligence, post-train and fine-tune for basic...
From Approval to Impact: Prioritize Results Over Perception
When I was 40, I really cared what people think about me and what I do. At almost 50, I only care about the results. I am cutting many activities to prioritize impact and maximize the value of time investment....

WEF Report Highlights AI Driving Organizational Transformation
Important report on the impact of AI in organizational transformation by the World Economic Forum. Happy to see Insilico presented as one of the case studies. https://t.co/rMr1W3aBDl https://t.co/dKcJAvvAHr

China AI Boom Peaks; Baidu Leads Profitably
The AI craze in China has peaked - Minimax briefly surpassed Baidu in market cap and is about the same now. Zhipu - very close. What is interesting is that Baidu is actually profitable and has $18B + in revenue....

12-Year AI Drug Expert Unfamiliar
In my 12 years in AI drug discovery, I have not heard of this company, have you? Original Bloomberg post by @AmberTongPW https://t.co/9C4LY1c5Um and full text by China Dailly https://t.co/z3xG5Y5HBI https://t.co/fnddeGtdEW
Approve Longevity Drugs for Disease First, Then Expand to Aging
The only sustainable path to development of longevity therapeutics is to get the potential longevity drug approved for a disease, then go for indication expansion and study it in the context of aging at different doses and regimens. To be...

Invasive BCI Advances Faster than Expected, Needs Major Backers
Pretty big news in the BCI world today. Before Insilico, I was in BCI. I did not expect invasive interfaces to progress so quickly. The future will be amazing and I hope that Elon and Google put some serious muscle...
Shanghai's
I arrived in Shanghai and can not recognize it - there is an @openclaw craze. All high-end Mac products are sold out and there is a National push for OpenClaw adoption to boost productivity. @steipete is a local hero. I...

Foundation Models Set to Transform Drug Discovery
Would you like to hear an opinion on how the future of drug discovery will look like as foundation models become more capable in drug discovery tasks? Check out our dialogue and the first pilot with the foundation model genius @ramin_m_h...

TopTown SuperDNA Aims to End Aging by 2028
We will solve aging or will die trying. Check out the TopTown SuperDNA project. It is no longer a concept - projected launch in Q3 2028. Fully-integrated residential-biotechnology-clinical infrastructure is key to longitudinal AI-powered drug discovery. https://t.co/LK5XaTci29
Science Secures $230M Series C for Longevity Tech
Exciting news in the world of longevity via deep technology. Congratulations to @khoslaventures and @lightspeedvp on this historic investment. IMHO, Science may be bigger than OpenAI